About BioCardia

We are a clinical-stage regenerative medicine company.

Our Mission: To bring to market comprehensive cell therapy solutions for the treatment of cardiovascular diseases with large unmet medical needs.

Our Pipeline: Our lead therapeutic candidate is the investigational CardiAMP™ Cell Therapy System, which provides an autologous bone marrow derived cell therapy (using a patient's own cells) for the treatment of two clinical indications - heart failure that develops after a heart attack and chronic myocardial ischemia.

Our second therapeutic candidate is the investigational CardiALLO™  Cell Therapy System, an allogeneic culture expanded "off the shelf" cell therapy derived from donor bone marrow cells that have been identified to meet specified criteria. This therapy has the potential to be advanced for many clinical indications including heart failure.



News

28 Oct

Cardiology Today

Ongoing trial assessing novel assay to determine response to cardiac regenerative therapy
Read More
11 May

University of Minnesota

Investigational Therapy Exploring Treatment of Heart Failure Seeks to Stimulate Body’s Natural Healing Response
Read More
16 Apr

Saint Joseph Mercy

St. Joseph Mercy Ann Arbor to perform clinical trial using stem cells to treat congestive heart failure
Read More
31 Jan

BioWorld Med Tech

Biocardia wins IDE for cell therapy as treatment for angina
Read More
03 Oct

BioWorld Med Tech

Biocardia presses on with Cardiamp pivotal trial to treat patients with heart failure
Read More
26 May

Med Latest

BioCardia® Helix Results in Higher Stem Cell Retention in Myocardium
Read More

press releases

11 Dec
2018 BioCardia Submits 510(K) Application To FDA For AVANCE Steerable Introducer For Transseptal Access To Heart
12 Nov
2018 Positive 12-Month Data on BioCardia's Investigational CardiAMP Cell Therapy System for Heart Failure Presented at American Heart Association Scientific Sessions 2018
08 Nov
2018 BioCardia Reports Third Quarter 2018 Financial Results and Business Highlights
06 Nov
2018 BioCardia Welcomes Cardiovascular Device Veteran Mark Schwartz as Vice President of Clinical Affairs
30 Oct
2018 BioCardia and CellProThera Partner for Clinical Trial and Marketing in Singapore of Early Stem Cell Therapy for Patients Following Myocardial Infarction
24 Sep
2018 Positive Data on BioCardia's Investigational CardiAMP Cell Therapy for Heart Failure Presented at Transcatheter Cardiovascular Therapeutics (TCT) Conference
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS